Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human HK3 Antibodies:
anti-Mouse (Murine) HK3 Antibodies:
anti-Rat (Rattus) HK3 Antibodies:
Go to our pre-filtered search.
Human Polyclonal HK3 Primary Antibody for IHC (p), WB - ABIN392753
Furuta, Nishi, Le Beau, Fernald, Yano, Bell: Sequence of human hexokinase III cDNA and assignment of the human hexokinase III gene (HK3) to chromosome band 5q35.2 by fluorescence in situ hybridization. in Genomics 1997
Show all 4 Pubmed References
Human Polyclonal HK3 Primary Antibody for WB - ABIN392754
Palmieri, Fitzgerald, Shreeve, Hua, Bronder, Weil, Davis, Stark, Merino, Kurek, Mehdorn, Davis, Steinberg, Meltzer, Aldape, Steeg: Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. in Molecular cancer research : MCR 2009
Developed risk assessment models for North Chinese patients with 4-50 ng/mL PSA to reduce unnecessary prostate biopsies and increase the detection rate of prostate cancer.
Data show positive associations of relative Gal-3 and relative PSA levels in prostate cancer patients, notably at early clinical time course.
Both the extent of comorbidity and the PSA doubling time should be taken into consideration when deciding on appropriate management and/or clinical trial eligibility at the time of PSA failure.
As restaging in advanced prostate cancer patients is often guided by increases in PSA levels, our results demonstrate that disease progression on enzalutamide can occur without rising PSA levels. Therefore, a disease monitoring strategy that includes imaging not entirely reliant on serial serum PSA measurement may more accurately identify disease progression.
Older men who underwent no PSA testing or incomplete testing were significantly more likely to be diagnosed with high-risk prostate cancer than those who were previously screened. It is reasonable to consider screening in healthy older men likely to benefit from early detection and treatment.
end-of-radiation PSA was significantly associated with survival endpoints in men who received treatment with definitive radiation and ADT. Whether the EOR PSA can be used to modulate treatment intensity merits further investigation.
the concentrations of insulin (show INS Antibodies), IGF-1 (show IGF1 Antibodies), IGFBP-3 (show IGFBP3 Antibodies) and their association with prostate size in patients with BPH (show GLI3 Antibodies)
Data suggest that occurrence of PSA failure was associated with increased risk of all-cause mortality (ACM) only in men with no or minimal, but not moderate-to-severe, comorbidity.
Annexin A2 (ANXA2) and prostate-specific antigen (PSA) proteins measured from biopsy tumour regions are unlikely to be good biomarkers for prediction of the clinical outcome of prostate cancer presenting with apparently localized disease.
Microenvironmental acidity determines qualitatively and quantitatively the release of extracellular vesicles by malignant prostate tumors. This leads to the spill-over of nanovesicles into the peripheral blood of prostate cancer patients, where the levels of tumor biomarkers expressed by exosomes, such as PSA-exosomes, may represent a novel, non-invasive diagnostic tool.
Hexokinase expression is highly enriched in neurons compared to astrocytes.
plastid HXK enzyme activities, location, function in signal transduction, and cross talk to plastid GUN1 protein (a (show GPR153 Antibodies) key signaling factor) were investigated. pHXK may be a node of convergence for sugar-mediated and PGE (show LIPF Antibodies)-derived signals.
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Its protein product is a protease present in seminal plasma. It is thought to function normally in the liquefaction of seminal coagulum, presumably by hydrolysis of the high molecular mass seminal vesicle protein. Serum level of this protein, called PSA in the clinical setting, is useful in the diagnosis and monitoring of prostatic carcinoma. Alternate splicing of this gene generates several transcript variants encoding different isoforms.
, HK III
, hexokinase type III
, P-30 antigen
, prostate specific antigen
, prostate-specific antigen
, hexokinase 3 (white cell)